ZENSAR TECHNOLOGIES LTD.

Zensar Technologies Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be shut for all designated persons and their immediate relatives starting from October 1, 2026. The purpose of this closure is to facilitate the consideration of the Unaudited (Standalone and Consolidated) Financial Results for the quarter and half-year ended September 30, 2026. The trading window is expected to reopen 48 hours after the declaration of these financial results. During this period, all designated individuals and their relatives are prohibited from trading in Zensar Technologies' shares.

Zensar Technologies Ltd announced an update regarding the merger of its US-based wholly-owned subsidiary, M3BI LLC, with Zensar Technologies Inc., USA. Following the in-principle approval granted by the Board of Directors, all requisite filings with relevant local authorities and state agencies for the merger of M3BI LLC were completed on August 13, 2026. The merger is set to become effective from September 1, 2026. This follows the earlier completion of filings for the merger of Bridgeview Life Sciences LLC with Zensar Technologies Inc. on July 31, 2026. Post-merger and consequential filings are still in process.

Zensar Technologies Ltd announced that the merger of its US-based wholly owned subsidiary, Bridgeview Life Sciences LLC, with Zensar Technologies Inc., USA, will be effective from August 1, 2026. All necessary filings with relevant local authorities and state agencies for this merger were completed on July 30, 2026. The company had previously granted in-principle approval for this merger, along with M3BI LLC, on July 29, 2026. Filings for the merger of M3BI LLC are still in progress. This update follows their earlier communication regarding the board's in-principle approval.

Zensar Technologies Ltd announced the approval of its Unaudited Standalone & Consolidated Financial Results for the quarter ended June 30, 2026. The Board of Directors met on July 29, 2026, to review and recommend these results along with the Limited Review Report. The meeting commenced at 5:00 p.m. (IST) and concluded at 08:05 p.m. (IST). The results were prepared in accordance with Indian Accounting Standard 34 and comply with SEBI Listing Regulations.

Zensar Technologies Limited's Board of Directors has granted in-principle approval for the merger of its US-based step-down subsidiaries, Bridgeview Life Sciences LLC and M3BI LLC, into Zensar Technologies Inc., USA. This strategic move aims to achieve greater business synergies, enhance operational efficiencies, and enable unified control of operations. The merger is expected to result in the cessation of Bridgeview Life Sciences LLC and M3BI LLC as separate entities. The transaction does not involve cash consideration or a change in Zensar Technologies Limited's shareholding pattern. Financial details for the merging entities as of March 31, 2026, show Bridgeview Life Sciences LLC with a net worth of $0.4 million and turnover of $4.74 million, and M3BI LLC with a net worth of $9.32 million and turnover of $46.8 million. Zensar Technologies Inc. reported a net worth of $74.66 million and turnover of $326.96 million.

Zensar Technologies Ltd announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors approved the results along with the Limited Review Report. The meeting commenced at 5:00 p.m. (IST) and concluded at 08:05 p.m. (IST). The results were prepared in accordance with Indian Accounting Standard 34 and reviewed by S R BC & CO LLP.

Zensar Technologies Ltd has submitted a revised Integrated Annual Report for the Financial Year 2025-26. The initial submission on July 8, 2026, required an update due to an improperly reflected RPG Group logo. The revised report, now available on the company's website, details the company's strategic focus on 'Accelerate Intelligence, Embrace Excellence,' emphasizing AI-native solutions, data-driven decision-making, and continuous improvement. The report covers corporate overview, strategic review, value creation across various capitals (financial, intellectual, manufactured, ESG, human, natural, social, and relationship), governance, and statutory reports. It highlights Zensar's commitment to digital and AI-native transformation, aiming to deliver superior client experiences and sustainable growth.

Zensar Technologies Ltd has announced that its Board of Directors will convene on July 29, 2026. The primary agenda item is to consider and approve the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026. The Limited Review Report for these results will also be taken on record. Additionally, the company has informed that the trading window for its securities will remain closed from July 1, 2026, and will reopen 48 hours after the declaration of the Q1-FY2026-27 financial results.

Zensar Technologies Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, in compliance with SEBI regulations. The report, which includes an Independent Practitioners’ Reasonable Assurance Report on BRSR Core KPIs by BSI Group India Pvt. Ltd., forms an integral part of the company's Integrated Annual Report. The disclosures are made on a consolidated basis. The company's primary business activities include IT Services, contributing 100% to turnover, with Digital Application Services accounting for 78% and Cloud Infrastructure and Security for 22%. Zensar serves a global customer base of 178 clients, including Fortune 2000 organizations, across various industry verticals, with exports contributing 88% to its total turnover.

Zensar Technologies Limited has announced its 63rd Annual General Meeting (AGM) will be held on Thursday, July 30, 2026, at 03:30 P.M. (IST) via Video Conferencing (VC)/Other Audio Visual Means (OAVM). The company has also released its Integrated Annual Report for the Financial Year 2025-26, along with the Notice of the AGM and other statutory reports. The report, themed 'Accelerate Intelligence, Embrace Excellence,' details the company's strategy, value creation across various capitals (financial, intellectual, manufactured, ESG, human, natural, social, and relationship), and governance. The report is being sent electronically to shareholders with registered email IDs and a web-link is provided for others. The Integrated Annual Report is also available on the company's investor relations website.